- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
PharmaNova, a leader in nanotechnology-based Drug Delivery Systems, is due to exhibit at the 2009 annual meeting of the American Association of Pharmaceutical Scientists (AAPS) scheduled in Los Angeles, CA, from November 8 - 12.
The Company will announce new technology breakthroughs in discussions with visitors to the exhibit. The meeting will be at Los Angeles Convention Center and the booth location is 2451.
NovaSperse(SM) technology is focused on the formation of stable amorphous nanoparticles with excellent reproducibility. This technology is being applied to both New Product Opportunities (NPOs) and Client Sponsored Projects (CSPs).
PharmaNova's proprietary NovaSperse(SM) technology offers proactive control of nanoparticle characteristics and is tailored to the unique chemistry of individual active pharmaceutical ingredients (APIs). PharmaNova's scientists are actively advancing the NovaSperse(SM) technology platform towards attaining a leadership position among nanotechnology-enabled drug delivery companies.
A nanometer is one-billionth of a meter; a human hair is roughly 100,000 nanometers wide; a human fingernail grows 1 nanometer every second; a sheet of paper is about 100,000 nanometers thick.
About PharmaNova Inc.
PharmaNova Inc. is a privately held, specialty pharmaceutical company founded on the re-positioning and enhancement of known drugs using its proprietary NovaSperse(SM) nanoparticle technology platform and other complementary drug delivery and formulation technologies. We address low-risk, fast-to-market products in areas of clear medical need and generate revenue from partnering and licensing strategies with commercialization partners worldwide. PharmaNova also provides contractual services for the NovaSperse(SM)-based formulation of client-owned APIs. PharmaNova's pipeline includes a (partnered) non-hormonal treatment for menopausal hot flashes and topical anti-infective and ophthalmic new product opportunities. PharmaNova and Altacor of Cambridge, England, have formed a strategic alliance to develop and commercialize a series of new prescription ophthalmic medical products based on PharmaNova's proprietary NovaSperse(SM) nanoparticle technology.
For more information, please click here
Director Business Development
Copyright © prnewswireIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Kalam: versatility personified August 1st, 2015
Gold-diamond nanodevice for hyperlocalised cancer therapy: Gold nanorods can be used as remote controlled nanoheaters delivering the right amount of thermal treatment to cancer cells, thanks to diamond nanocrystals used as temperature sensors August 1st, 2015
Take a trip through the brain July 30th, 2015
Sol-gel capacitor dielectric offers record-high energy storage July 30th, 2015
Self-assembling, biomimetic membranes may aid water filtration August 1st, 2015
March 2016; 6th Int'l Conference on Nanostructures in Iran July 29th, 2015
Nanometrics Announces Upcoming Investor Events July 28th, 2015
European Technology Platform for Nanomedicine and ENATRANS European Consortium Launch the 2nd edition of the Nanomedicine Award: The Award to be presented at BIO-Europe conference in Munich, November 2015 July 30th, 2015
New computer model could explain how simple molecules took first step toward life: Two Brookhaven researchers developed theoretical model to explain the origins of self-replicating molecules July 28th, 2015
Spintronics: Molecules stabilizing magnetism: Organic molecules fixing the magnetic orientation of a cobalt surface/ building block for a compact and low-cost storage technology/ publication in Nature Materials July 25th, 2015